Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

196
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
196
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

189
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
189
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

480
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
480
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.3K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.3K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Lesion network localization of depression in multiple sclerosis.

Nature. Mental health·2026
Same author

A Case of Persistent Ataxia and Atypical Brain Lesions: From the National Multiple Sclerosis Society Case Conference Proceedings.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

A cell-intrinsic glucocorticoid biosynthesis and sensing circuit maintains a homeostatic Th17 cell state.

Immunity·2026
Same author

Comorbidities and lifestyle changes as predictors of the multiple sclerosis prodrome: A prospective cohort study.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Cell-type- and state-resolved transcriptomics uncovers distinct T cell and monocyte dysregulation in multiple sclerosis.

Cell reports·2026
Same author

Nasal administration of Protollin enhances monocyte phagocytosis and decreases CD8<sup>+</sup> T cell cytotoxicity in subjects with early Alzheimer's disease: a Phase 1 clinical trial.

npj aging·2026

関連する実験動画

Updated: Jan 14, 2026

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

1.8K

小児多発性硬化症の疾患修飾療法

Elizabeth Wilson1, Tanuja Chitnis2

  • 1Department of Pediatrics, Multiple Sclerosis and Neuroimmunology Center, Division of Neurology, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

Handbook of clinical neurology
|January 12, 2026
PubMed
まとめ
この要約は機械生成です。

小児多発性硬化症(MS)は炎症性が高く、再発が多い。承認されたフィンゴリモドを含む高有効性治療は、小児MSの管理に不可欠であり、現在、成人向け治療薬も多くが試用されている。

キーワード:
DMT障害病変MRI多発性硬化症小児再発療法治療

さらに関連する動画

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.6K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.5K

関連する実験動画

Last Updated: Jan 14, 2026

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

1.8K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.6K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.5K

科学分野:

  • 神経学; 小児科学; 免疫学

背景:

  • 小児および青年期におけるMS発症はますます認識されている。
  • 小児MSは、成人MSと比較して、再発率が高く、非常に炎症性の高い疾患経過を示す。

研究 の 目的:

  • 小児MSの疾患経過の理解をレビューすること。
  • 小児MSの現在の管理戦略と治療研究の概要を説明すること。

主な方法:

  • 小児MS治療に関するオープンラベルおよび後向き研究のレビュー。
  • 小児MSの承認済みおよび調査中の治療法の議論。

主要な成果:

  • 小児MSには高有効性の疾患修飾療法が推奨される。
  • フィンゴリモド(ジレニア)は多くの地域で小児MSに承認されている。
  • いくつかの成人MS治療薬が小児への使用を目的として調査中である。

結論:

  • 小児MSの理解は著しく進歩した。
  • 小児MSの効果的な管理には、高有効性治療が含まれる。
  • 進行中の研究により、若いMS患者の治療選択肢が拡大している。